Literature DB >> 26474564

How Long to Treat with Denosumab.

Aline G Costa, John P Bilezikian.   

Abstract

Chronic diseases typically require long-term treatment. Osteoporosis is a chronic disease in which fracture risk is high, and treatment is required to prevent fragility fractures. Denosumab is a fully human monoclonal antibody that inhibits RANK ligand, a powerful bone-resorbing cytokine. It is approved for individuals with osteoporosis who are at high risk for fracture. Clinical trial results confirm that denosumab is effective over the long term and has an excellent safety profile. In patients at high risk for osteoporotic fracture, therefore, long-term treatment with denosumab appears to present an attractive benefit profile.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26474564     DOI: 10.1007/s11914-015-0295-7

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  37 in total

Review 1.  Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.

Authors:  Ana Boquete-Castro; Gerardo Gómez-Moreno; José Luis Calvo-Guirado; Antonio Aguilar-Salvatierra; Rafael Arcesio Delgado-Ruiz
Journal:  Clin Oral Implants Res       Date:  2015-02-02       Impact factor: 5.977

2.  Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study.

Authors:  Jacques P Brown; David W Dempster; Beiying Ding; Ricardo Dent-Acosta; Javier San Martin; Andreas Grauer; Rachel B Wagman; Jose Zanchetta
Journal:  J Bone Miner Res       Date:  2011-11       Impact factor: 6.741

Review 3.  Do RANKL inhibitors (denosumab) affect inflammation and immunity?

Authors:  S Ferrari-Lacraz; S Ferrari
Journal:  Osteoporos Int       Date:  2010-06-23       Impact factor: 4.507

4.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

5.  Meta-analysis: excess mortality after hip fracture among older women and men.

Authors:  Patrick Haentjens; Jay Magaziner; Cathleen S Colón-Emeric; Dirk Vanderschueren; Koen Milisen; Brigitte Velkeniers; Steven Boonen
Journal:  Ann Intern Med       Date:  2010-03-16       Impact factor: 25.391

Review 6.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

7.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

Authors:  Paul D Miller; Michael A Bolognese; E Michael Lewiecki; Michael R McClung; Beiying Ding; Matthew Austin; Yu Liu; Javier San Martin
Journal:  Bone       Date:  2008-04-26       Impact factor: 4.398

8.  Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.

Authors:  Socrates Papapoulos; Roland Chapurlat; Cesar Libanati; Maria Luisa Brandi; Jacques P Brown; Edward Czerwiński; Marc-Antoine Krieg; Zulema Man; Dan Mellström; Sebastião C Radominski; Jean-Yves Reginster; Heinrich Resch; José A Román Ivorra; Christian Roux; Eric Vittinghoff; Matthew Austin; Nadia Daizadeh; Michelle N Bradley; Andreas Grauer; Steven R Cummings; Henry G Bone
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

9.  The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.

Authors:  S Papapoulos; K Lippuner; C Roux; C J F Lin; D L Kendler; E M Lewiecki; M L Brandi; E Czerwiński; E Franek; P Lakatos; C Mautalen; S Minisola; J Y Reginster; S Jensen; N S Daizadeh; A Wang; M Gavin; C Libanati; R B Wagman; H G Bone
Journal:  Osteoporos Int       Date:  2015-07-23       Impact factor: 4.507

10.  The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.

Authors:  Henry G Bone; Roland Chapurlat; Maria-Luisa Brandi; Jacques P Brown; Edward Czerwinski; Marc-Antoine Krieg; Dan Mellström; Sebastião C Radominski; Jean-Yves Reginster; Heinrich Resch; Jose A Román Ivorra; Christian Roux; Eric Vittinghoff; Nadia S Daizadeh; Andrea Wang; Michelle N Bradley; Nathalie Franchimont; Michelle L Geller; Rachel B Wagman; Steven R Cummings; Socrates Papapoulos
Journal:  J Clin Endocrinol Metab       Date:  2013-08-26       Impact factor: 5.958

View more
  1 in total

1.  Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years.

Authors:  Chi Zhang; Fan Zhang; Guanzhao Liang; Xianshang Zeng; Weiguang Yu; Zhidao Jiang; Jie Ma; Mingdong Zhao; Min Xiong; Keke Gui; Fenglai Yuan; Weiping Ji
Journal:  BMC Musculoskelet Disord       Date:  2018-11-30       Impact factor: 2.362

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.